Multivalent metal salts of boronic acids
First Claim
Patent Images
1. A pharmaceutical formulation adapted for oral administration and comprising a) a first species selected from the group consisting of a boronic acid of formula (III), said acid when in the form of a boronate ion thereof, an equilibrium form of said boronic acid and of said boronate ion, and combinations thereof:
-
wherein Y comprises a moiety which, together with the aminoboronic acid residue —
NHCH(R9)—
B(OH)2, has affinity for the substrate binding site of thrombin; and
R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —
(CH2)m—
W where m is from 2, 3, 4 or 5 and W is —
OH or halogen; and
(b) a second species selected from the group consisting of multivalent metal ions.
3 Assignments
0 Petitions
Accused Products
Abstract
Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.
-
Citations
28 Claims
-
1. A pharmaceutical formulation adapted for oral administration and comprising
a) a first species selected from the group consisting of a boronic acid of formula (III), said acid when in the form of a boronate ion thereof, an equilibrium form of said boronic acid and of said boronate ion, and combinations thereof: -
wherein Y comprises a moiety which, together with the aminoboronic acid residue —
NHCH(R9)—
B(OH)2, has affinity for the substrate binding site of thrombin; and
R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —
(CH2)m—
W where m is from 2, 3, 4 or 5 and W is —
OH or halogen; and
(b) a second species selected from the group consisting of multivalent metal ions. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 17, 18, 19, 20, 21, 22, 23, 24)
-
- 11. The formulation of claim 11 wherein aa1 is selected from Phe, Dpa and wholly or partially hydrogenated analogues thereof.
-
25. A medicament adapted for oral administration and comprising a therapeutically effective amount of a multivalent metal salt of a boronic acid which is a selective thrombin inhibitor and has a neutral aminoboronic acid residue capable of binding to the thrombin S1 subsite linked through a peptide linkage to a hydrophobic moiety capable of binding to the thrombin S2 and 53 subsites, the salt comprising a cation having a valency n and having an observed stoichiometry consistent with a notional stoichiometry (boronic acid:
- cation) of n;
1. - View Dependent Claims (26, 27)
- cation) of n;
-
28. A method for preventing thrombosis in a haemodialysis circuit of a patient, for preventing a cardiovascular event in a patient with end stage renal disease, for preventing venous thromboembolic events in a patient receiving chemotherapy through an indwelling catheter, for preventing thromboembolic events in a patient undergoing a lower limb arterial reconstructive procedure, or for treating by way of therapy or prophylaxis an arterial disease selected from acute coronary syndromes, cerebrovascular thrombosis, peripheral arterial occlusion and arterial thrombosis resulting from atrial fibrillation, valvular heart disease, arterio-venous shunts, indwelling catheters or coronary stents, the method comprising parenterally administering to a mammal a therapeutically effective amount of a salt of a pharmaceutically acceptable multivalent metal and a peptide boronic acid of formula (IV):
Specification